Minimising Risk And Maximising Efficiency By Taking A Strategic Approach To Comparative Trial Supply
Widely acknowledged to be a prerequisite for formulary listing and even successful licensure, comparator drugs and co-therapies are used within an estimated two-thirds of clinical trials. Nicholas Griffin at Almac Clinical Services evaluates how to minimise risk and increase efficiency when taking a strategic approach to comparative trial supply.
Read more on this article by clicking here.
Our Expert
Almac Clinical Services
Guided by our extensive clinical supply experience and expertise, Almac Clinical Services is recognised as an innovative, global solution provider within the specialised and complex market of clinical trial supply.
Our integrated and adaptable solutions offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.
Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.
